FDA Inspection 1136953 — Daniel Flynn, MD
The FDA completed an inspection of Daniel Flynn, MD on March 3, 2021 in Boise, ID. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 3, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Boise, ID (United States)
Additional Details
Clinical Investigator (CI)